AR029643A1 - Poblacion de rotavirus atenuados, variantes y recombinantes de dichos rotavirus atenuados, metodo para producir dichas poblaciones de rotavirus purificadas, composiciones de vacunas que comprenden dichos virus atenuados, vivos, metodo para obtener dichas vacunas y un metodo para prevenir en el hombr - Google Patents

Poblacion de rotavirus atenuados, variantes y recombinantes de dichos rotavirus atenuados, metodo para producir dichas poblaciones de rotavirus purificadas, composiciones de vacunas que comprenden dichos virus atenuados, vivos, metodo para obtener dichas vacunas y un metodo para prevenir en el hombr

Info

Publication number
AR029643A1
AR029643A1 ARP000104215A ARP000104215A AR029643A1 AR 029643 A1 AR029643 A1 AR 029643A1 AR P000104215 A ARP000104215 A AR P000104215A AR P000104215 A ARP000104215 A AR P000104215A AR 029643 A1 AR029643 A1 AR 029643A1
Authority
AR
Argentina
Prior art keywords
rotavirus
damaged
populations
variants
virused
Prior art date
Application number
ARP000104215A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919468.0A external-priority patent/GB9919468D0/en
Priority claimed from GBGB9927336.9A external-priority patent/GB9927336D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR029643A1 publication Critical patent/AR029643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen y reivindican poblaciones de rotavirus atenuados que comprenden una sola o sustancialmente una sola variante definida por una secuencia de nucleotidos que codifica al menos una de las proteínas virales principales denominadas VP4 y VP7. Particularmente se trata de variantes de poblaciones de rotavirus en la que dicha variante es una variante en la que el gen de DP4 comprende una secuencia de nucleotidos que comprende al menos una de las siguientes: una base de adenina (A) en la posicion 788, una base de adenina (A) en la posicion 802 y una base de tinina (T) en la posicion 501 desde el codon de iniciacion. También se reivindican los objetos restantes mencionados en el título.
ARP000104215A 1999-08-17 2000-08-15 Poblacion de rotavirus atenuados, variantes y recombinantes de dichos rotavirus atenuados, metodo para producir dichas poblaciones de rotavirus purificadas, composiciones de vacunas que comprenden dichos virus atenuados, vivos, metodo para obtener dichas vacunas y un metodo para prevenir en el hombr AR029643A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9919468.0A GB9919468D0 (en) 1999-08-17 1999-08-17 Vaccine
GBGB9927336.9A GB9927336D0 (en) 1999-11-18 1999-11-18 Vaccine

Publications (1)

Publication Number Publication Date
AR029643A1 true AR029643A1 (es) 2003-07-10

Family

ID=26315853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104215A AR029643A1 (es) 1999-08-17 2000-08-15 Poblacion de rotavirus atenuados, variantes y recombinantes de dichos rotavirus atenuados, metodo para producir dichas poblaciones de rotavirus purificadas, composiciones de vacunas que comprenden dichos virus atenuados, vivos, metodo para obtener dichas vacunas y un metodo para prevenir en el hombr

Country Status (42)

Country Link
US (4) US7285280B1 (es)
EP (1) EP1212084B1 (es)
JP (3) JP2003507040A (es)
KR (1) KR100695599B1 (es)
CN (1) CN100379451C (es)
AP (1) AP1768A (es)
AR (1) AR029643A1 (es)
AT (1) ATE327765T1 (es)
AU (1) AU767885B2 (es)
BG (1) BG65314B1 (es)
BR (1) BRPI0013357B8 (es)
CA (1) CA2379196C (es)
CO (1) CO5580165A1 (es)
CY (2) CY1106103T1 (es)
CZ (1) CZ302173B6 (es)
DE (2) DE122006000026I1 (es)
DK (1) DK1212084T3 (es)
DZ (1) DZ3219A1 (es)
EA (1) EA005952B1 (es)
ES (1) ES2260046T3 (es)
FR (1) FR06C0018I2 (es)
HK (1) HK1046860B (es)
HU (2) HU228975B1 (es)
IL (3) IL147926A0 (es)
LU (1) LU91251I2 (es)
MA (1) MA25489A1 (es)
MX (1) MXPA02001648A (es)
MY (1) MY133158A (es)
NL (1) NL300233I2 (es)
NO (2) NO328112B1 (es)
NZ (1) NZ517131A (es)
OA (1) OA12312A (es)
PE (1) PE20010487A1 (es)
PL (1) PL205550B1 (es)
PT (1) PT1212084E (es)
SI (1) SI1212084T1 (es)
SK (1) SK287261B6 (es)
TR (1) TR200200420T2 (es)
TW (1) TWI283270B (es)
UA (1) UA77388C2 (es)
UY (1) UY26297A1 (es)
WO (1) WO2001012797A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000026I1 (de) * 1999-08-17 2006-10-12 Glaxosmithkline Biolog Sa Methoden um Rotavirusvarianten zu trennen und lebender attenuierter Rotavirus impfstoff
US6592869B2 (en) * 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
GB0020089D0 (en) * 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
KR20030026654A (ko) * 2001-09-26 2003-04-03 주식회사 씨트리 인간 로타바이러스의 활성을 저해하는 항체의 생산용 항원및 그의 제조방법과 이용
GB0414787D0 (en) 2004-07-01 2004-08-04 Glaxosmithkline Biolog Sa Method
SG147465A1 (en) * 2003-09-02 2008-11-28 Glaxosmithkline Biolog Sa Vaccine
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
ES2534637T3 (es) * 2005-08-17 2015-04-27 Glaxosmithkline Biologicals S.A. Vacuna de rotavirus que induce protección cruzada heterotípica
CA2630220C (en) 2005-11-22 2020-10-13 Doris Coit Norovirus and sapovirus antigens
KR101051986B1 (ko) * 2006-09-28 2011-07-26 중앙대학교 산학협력단 인간로타바이러스 및 이를 이용한 백신 조성물
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2010132561A2 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
CN102470170B (zh) 2009-07-13 2015-03-18 巴拉特生物技术国际有限公司 用作轮状病毒疫苗的组合物及其方法
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
RU2643929C2 (ru) 2012-04-23 2018-02-06 Бхарат Байотек Интернэшнл Лимитед Новые ротавирусные вакцинные композиции и способ получения вышеуказанных композиций
BR112015004085A2 (pt) * 2012-08-27 2017-08-08 Murdoch Childrens Res Inst método para cultivar uma cepa de rotavírus (rv); método para gerar uma rv3 atenuada em células vero; rv3 adaptada à vero isolada; composição de rv morto ou vivo atenuado; método para vacinar um indivíduo humano contra infecção por rv; método para tratar um indivíduo humano com uma infecção por rv ou em risco de desenvolver uma infecção ou reinfecção por rv; uso da rv3 de vero; anticorpo isolado; e método para detectar ou monitorar a rv3 de vero
CN106167518B (zh) * 2015-05-21 2021-01-15 厦门大学 截短的轮状病毒vp4蛋白及其用途
CN108431214B (zh) 2015-10-05 2022-03-01 美国政府(由卫生和人类服务部的部长所代表) 人轮状病毒g9p[6]毒株和作为疫苗的用途
CN108367164A (zh) * 2015-12-18 2018-08-03 默沙东公司 热稳定的轮状病毒疫苗制剂及其使用方法
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
CN110856493B (zh) * 2018-08-20 2022-02-25 中国烟草总公司黑龙江省公司牡丹江烟草科学研究所 一种植物病毒弱毒疫苗组合物、弱毒疫苗保存方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5927323B2 (ja) * 1976-10-12 1984-07-05 花王株式会社 歯みがき組成物
US4341763A (en) * 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4571385A (en) * 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
US4624850A (en) * 1984-02-09 1986-11-25 Royal Children's Hospital Research Foundation Live attenuated human rotavirus vaccine
US5626851A (en) * 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
ES2121841T3 (es) * 1990-11-16 1998-12-16 Childrens Hosp Medical Center Una vacuna para proporcionar proteccion inmunologica contra enfermedades de rotavirus en humanos.
US5471385A (en) * 1992-05-21 1995-11-28 Tsubakimoto Chain Co. Routeless guiding method for moving body
US5773009A (en) * 1994-04-15 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services Rotavirus strain G9P11
WO1996001651A1 (en) * 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6403098B1 (en) * 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
EP0939648B1 (en) * 1996-09-26 2007-11-07 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DE122006000026I1 (de) * 1999-08-17 2006-10-12 Glaxosmithkline Biolog Sa Methoden um Rotavirusvarianten zu trennen und lebender attenuierter Rotavirus impfstoff

Also Published As

Publication number Publication date
NZ517131A (en) 2003-07-25
IL147926A0 (en) 2002-08-14
EP1212084B1 (en) 2006-05-31
FR06C0018I2 (fr) 2007-04-27
HU228975B1 (en) 2013-07-29
ES2260046T3 (es) 2006-11-01
SI1212084T1 (sl) 2006-08-31
CN100379451C (zh) 2008-04-09
KR100695599B1 (ko) 2007-03-14
AP1768A (en) 2007-08-16
NL300233I1 (nl) 2006-09-01
SK287261B6 (sk) 2010-04-07
HUS1300072I1 (hu) 2019-11-28
JP2011045374A (ja) 2011-03-10
ATE327765T1 (de) 2006-06-15
NO2010011I1 (no) 2010-06-07
EA200200142A1 (ru) 2002-08-29
CZ302173B6 (cs) 2010-11-24
IL147926A (en) 2008-03-20
OA12312A (en) 2006-05-12
CA2379196C (en) 2015-05-26
CZ2002522A3 (cs) 2002-05-15
SK2432002A3 (en) 2002-09-10
CO5580165A1 (es) 2005-11-30
BG65314B1 (bg) 2008-01-31
PL354135A1 (en) 2003-12-29
NO328112B1 (no) 2009-12-07
WO2001012797A2 (en) 2001-02-22
AP2002002424A0 (en) 2002-03-31
KR20020092344A (ko) 2002-12-11
CY2006004I1 (el) 2009-11-04
HUP0203335A3 (en) 2004-07-28
US7285280B1 (en) 2007-10-23
CY2006004I2 (el) 2009-11-04
NO2010011I2 (no) 2015-02-02
PT1212084E (pt) 2006-07-31
DE122006000026I1 (de) 2006-10-12
WO2001012797A3 (en) 2001-08-02
AU6996100A (en) 2001-03-13
US20090130145A1 (en) 2009-05-21
PE20010487A1 (es) 2001-06-23
JP2007319164A (ja) 2007-12-13
AU767885B2 (en) 2003-11-27
US7790179B2 (en) 2010-09-07
HUP0203335A1 (hu) 2003-02-28
EP1212084A2 (en) 2002-06-12
DK1212084T3 (da) 2006-07-10
NO20020763D0 (no) 2002-02-15
NO20020763L (no) 2002-04-16
IL188686A0 (en) 2008-04-13
NL300233I2 (nl) 2006-10-02
MXPA02001648A (es) 2002-08-06
DZ3219A1 (fr) 2001-02-22
BR0013357A (pt) 2002-04-30
DE60028390T2 (de) 2006-11-02
EA005952B1 (ru) 2005-08-25
CY1106103T1 (el) 2010-07-28
BRPI0013357B8 (pt) 2021-05-25
BRPI0013357B1 (pt) 2016-08-02
JP2003507040A (ja) 2003-02-25
CN1379683A (zh) 2002-11-13
LU91251I9 (es) 2018-12-31
MY133158A (en) 2007-10-31
DE60028390D1 (de) 2006-07-06
HK1046860A1 (en) 2003-01-30
TWI283270B (en) 2007-07-01
PL205550B1 (pl) 2010-04-30
BG106417A (en) 2003-04-30
LU91251I2 (fr) 2006-08-14
HK1046860B (zh) 2006-10-06
CA2379196A1 (en) 2001-02-22
US20080063662A1 (en) 2008-03-13
US7790180B2 (en) 2010-09-07
UY26297A1 (es) 2001-03-16
UA77388C2 (uk) 2006-12-15
FR06C0018I1 (es) 2006-07-21
MA25489A1 (fr) 2002-07-01
TR200200420T2 (tr) 2002-05-21
US20080057082A1 (en) 2008-03-06
JP5474720B2 (ja) 2014-04-16

Similar Documents

Publication Publication Date Title
AR029643A1 (es) Poblacion de rotavirus atenuados, variantes y recombinantes de dichos rotavirus atenuados, metodo para producir dichas poblaciones de rotavirus purificadas, composiciones de vacunas que comprenden dichos virus atenuados, vivos, metodo para obtener dichas vacunas y un metodo para prevenir en el hombr
Bruening [37] Compilation of self-cleaving sequences from plant virus satellite RNAs and other sources
DK1086207T3 (da) Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
ES2075901T3 (es) Sistemas de expresion de virus recombinantes de arn con cadena negativa y vacunas.
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
RS20050741A (en) Pharmaceutical compositions for hepatitis c viral protease inhibitors
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
CY1115010T1 (el) ΕΝΑΣ ΜΟΛΥΣΜΑΤΙΚΟΣ cDNA ΚΛΩΝΟΣ ΤΟΥ ΙΟΥ ΤΟΥ ΧΟΙΡΕΙΟΥ ΑΝΑΠΑΡΑΓΩΓΙΚΟΥ ΚΑΙ ΑΝΑΠΝΕΥΣΤΙΚΟΥ ΣΥΝΔΡΟΜΟΥ ΒΟΡΕΙΟΥ ΑΜΕΡΙΚΗΣ (PRRS) ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΟΥ
BRPI0410702A (pt) polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
DE59410380D1 (de) Endosomolytisch wirksame partikel
BRPI9701774B8 (pt) cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
DK1147212T3 (da) T-hjælpecelle-epitoper
BR0112020A (pt) Partìculas tipo vìrus de bvdv
IL168374A (en) Vaccines against west nile virus
ATE320480T1 (de) Von der seebarsch epinephelus coioides derivierte unsterbliche zellinie und ihre verwendungen
AR021670A1 (es) UNA COMPOSICIoN QUE COMPRENDE 9-(2-((BIS(PIVALOILOXI)METIL)FOSFONO)METOXI)ETIL)ADENINA Y UN MÉTODO PARA SU PREPARACIoN
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
DK1676586T3 (da) Fremgangsmåde til adskillelse af rotavirusvarianter samt levende, svækket rotavirusvaccine
PE20001331A1 (es) Identificacion de genotipos senv
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
EP1074624A4 (en) GENE 62 OF THE ATTENUATED VARICELLA VIRUS STRAIN OKA AND METHOD FOR IDENTIFYING THE VIRUS STRAIN ATTENUATED VARICELLA VACCINE USING THE SAME
DE60335139D1 (de) Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
Hurst Expression of the aquareovirus fusion protein is regulated by translation from a non-AUG initiated-cistron of a polycistronic genome segment.

Legal Events

Date Code Title Description
FG Grant, registration